Presentation TCT 2016 Key Note Lecture II. Regulatory Reform of Medical Device Approvals by the European Commission Motivating Factors, Anticipated Changes, and Timelines Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Alan G. Fraser October 31, 2016
Presentation TCT 2016 Key Note Lecture I. FDA/CDRH State of the Union Presenter: Matthew G. Hillebrenner, Gregg W. Stone, Jeffrey Shuren October 31, 2016
Presentation TCT 2016 The FDA Town Hall Meeting: Evolution of a Decades Long Collaboration Between Physician-Scientists, Industry, Regulators, and Payors Presenter: Matthew G. Hillebrenner, Gregg W. Stone October 31, 2016
News Industry News Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease October 31, 2016
News Conference News TCT 2016 EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo. Michael O'Riordan October 31, 2016
News Conference News TCT 2016 EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease Michael O'Riordan October 31, 2016
Presentation TCT 2016 EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone October 31, 2016
News Conference News TCT 2016 Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI Yael L. Maxwell October 31, 2016
News Conference News TCT 2016 BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year TCT Daily Staff October 30, 2016
Presentation TCT 2016 Update on RCTs in FMR, and First Report of the COAPT Roll-in Patients Presenter: Alec S. Vahanian, Ralph Stephan von Bardeleben, Gregg W. Stone October 30, 2016
Presentation TCT 2016 Early and Late Results With the Wavecrest LAA Occluder (and Future Studies) Presenter: Vivek Y. Reddy, Steven J. Yakubov, Gregg W. Stone October 30, 2016
Presentation TCT 2016 Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint? Presenter: Peter Juni, E. Magnus Ohman, Gregg W. Stone October 30, 2016
Presentation TCT 2016 Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion? Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone October 30, 2016
Presentation TCT 2016 BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari October 30, 2016
Presentation TCT 2016 BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen October 30, 2016
Presentation TCT 2016 ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease Presenter: Gregg W. Stone, Wayne B. Batchelor, Ziad A. Ali October 30, 2016
News Opinion Editor's Corner TCT 2016 TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever Shelley Wood October 24, 2016
News Conference News ESC 2016 Day or Night, STEMI Patients Receive Similar Levels of Quality Care L.A. McKeown August 31, 2016
News Conference News ESC 2016 NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents? Shelley Wood August 30, 2016
News Daily News One Map to Guide Them All: The Physician Who Hopes to Connect the Cardiology Dots Michael H. Wilson August 15, 2016